Genetic causes of vascular malformations

Human Molecular Genetics

Volumn 16, Issue R2, 2007, Pages

  Brouillard, Pascal ^a   Vikkula, Miikka ^a  

^a DE DUVE INSTITUTE   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ARTERIOVENOUS MALFORMATION; BIOLOGICAL MODEL; BLOOD VESSEL; BRAIN ARTERIOVENOUS MALFORMATION; CAPILLARY; CONGENITAL DISORDER; CONGENITAL MALFORMATION; GENETICS; HUMAN; LYMPHATIC SYSTEM DISEASE; LYMPHEDEMA; PATHOLOGY; RENDU OSLER WEBER DISEASE; REVIEW;

ARTERIOVENOUS MALFORMATIONS; BLOOD VESSELS; CAPILLARIES; CONGENITAL ABNORMALITIES; HUMANS; INTRACRANIAL ARTERIOVENOUS MALFORMATIONS; LYMPHATIC ABNORMALITIES; LYMPHEDEMA; MODELS, BIOLOGICAL; TELANGIECTASIA, HEREDITARY HEMORRHAGIC;

EID: 84866158884     PISSN: 09646906     EISSN: 14602083     Source Type: Journal    
DOI: 10.1093/hmg/ddm211     Document Type: Article

References (116)

1. Mulliken, J.B. and Glowacki, J. (1982) Hemangiomas and vascular malformations in infants and children: a classification based on endothelial characteristics. Plast. Reconstr. Surg., 69, 412-422.
2. Boon, L.M., Mulliken, J.B., Vikkula, M., Watkins, H., Seidman, J., Olsen, B.R. and Warman, M.L. (1994) Assignment of a locus for dominantly inherited venous malformations to chromosome 9p. Hum. Mol. Genet., 3, 1583-1587.
3. Boon, L.M., Mulliken, J.B., Enjolras, O. and Vikkula, M. (2004) Glomuvenous malformation (glomangioma) and venous malformation: distinct clinicopathologic and genetic entities. Arch. Dermatol., 140, 971-976.
4. Tian, X.L., Kadaba, R., You, S.A., Liu, M., Timur, A.A., Yang, L., Chen, Q., Szafranski, P., Rao, S., Wu, L. et al. (2004) Identification of an angiogenic factor that when mutated causes susceptibility to Klippel-Trenaunay syndrome. Nature, 427, 640-645.
5. Barker, K.T., Foulkes, W.D., Schwartz, C.E., Labadie, C., Monsell, F., Houlston, R.S. and Harper, J. (2006) Is the E133K allele of VG5Q associated with Klippel-Trenaunay and other overgrowth syndromes? J. Med. Genet., 43, 613-614.
6. Gutierrez, S., Magano, L., Delicado, A., Mori, M.A., de Torres, M.L., Fernandez, L., Palomares, M., Fernandez, E., Tarduchy, G.R., Molano, J. et al. (2006) The G397A (E133K) change in the AGGF1 (VG5Q) gene is a single nucleotide polymorphism in the Spanish population. Am. J. Med. Genet. A, 140, 2832-2833.
7. Vikkula, M., Boon, L.M., Carraway, K.L., III, Calvert, J.T., Diamonti, A.J., Goumnerov, B., Pasyk, K.A., Marchuk, D.A., Warman, M.L., Cantley, L.C. et al. (1996) Vascular dysmorphogenesis caused by an activating mutation in the receptor tyrosine kinase TIE2. Cell, 87, 1181-1190.
8. Wouters, V., Boon, L.M., Mulliken, J.B. and Vikkula, M. TIE2 and cutaneomucosal venous malformation. In Epstein, C., Erickson, R.P. and Wynshaw-Boris, A. (eds), Inborn Errors of Development 2ed, Oxford University Press, Inc., in press.
9. Calvert, J.T., Riney, T.J., Kontos, C.D., Cha, E.H., Prieto, V.G., Shea, C.R., Berg, J.N., Nevin, N.C., Simpson, S.A., Pasyk, K.A. et al. (1999) Allelic and locus heterogeneity in inherited venous malformations. Hum. Mol. Genet., 8, 1279-1289.
10. Nobuhara, Y., Onoda, N., Fukai, K., Hosomi, N., Ishii, M., Wakasa, K., Nishihara, T., Ishikawa, T. and Hirakawa, K. (2006) TIE2 gain-of-function mutation in a patient with pancreatic lymphangioma associated with blue rubber-bleb nevus syndrome: report of a case. Surg. Today, 36, 283-286.
11. Brouillard, P., Boon, L.M., Mulliken, J.B., Enjolras, O., Ghassibe, M., Warman, M.L., Tan, O.T., Olsen, B.R. and Vikkula, M. (2002) Mutations in a novel factor, glomulin, are responsible for glomuvenous malformations ('glomangiomas'). Am. J. Hum. Genet., 70, 866-874.
12. Dumont, D.J., Gradwohl, G., Fong, G.H., Puri, M.C., Gertsenstein, M., Auerbach, A. and Breitman, M.L. (1994) Dominant-negative and targeted null mutations in the endothelial receptor tyrosine kinase, tek, reveal a critical role in vasculogenesis of the embryo. Genes Dev., 8, 1897-1909.
13. Maisonpierre, P.C., Suri, C., Jones, P.F., Bartunkova, S., Wiegand, S.J., Radziejewski, C., Compton, D., McClain, J., Aldrich, T.H., Papadopoulos, N. et al. (1997) Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science, 277, 55-60.
14. Valenzuela, D.M., Griffiths, J.A., Rojas, J., Aldrich, T.H., Jones, P.F., Zhou, H., McClain, J., Copeland, N.G., Gilbert, D.J., Jenkins, N.A. et al. (1999) Angiopoietins 3 and 4: diverging gene counterparts in mice and humans. Proc. Natl Acad. Sci. USA, 96, 1904-1909.
15. Kontos, C.D., Stauffer, T.P., Yang, W.P., York, J.D., Huang, L., Blanar, M.A., Meyer, T. and Peters, K.G. (1998) Tyrosine 1101 of Tie2 is the major site of association of p85 and is required for activation of phosphatidylinositol 3-kinase and Akt. Mol. Cell. Biol., 18, 4131-4140.
16. Sato, T.N., Tozawa, Y., Deutsch, U., Wolburg-Buchholz, K., Fujiwara, Y., Gendron-Maguire, M., Gridley, T., Wolburg, H., Risau, W. and Qin, Y. (1995) Distinct roles of the receptor tyrosine kinases Tie-1 and Tie-2 in blood vessel formation. Nature, 376, 70-74.
17. Lelievre, E., Bourbon, P.M., Duan, L.J., Nussbaum, R.L. and Fong, G.H. (2005) Deficiency in the p110alpha subunit of PI3K results in diminished Tie2 expression and Tie2(2/2)-like vascular defects in mice. Blood, 105, 3935-3938.
18. Morris, P.N., Dunmore, B.J. and Brindle, N.P. (2006) Mutant Tie2 causing venous malformation signals through Shc. Biochem. Biophys. Res. Commun., 346, 335-338.
19. Kobayashi, H., DeBusk, L.M., Babichev, Y.O., Dumont, D.J. and Lin, P.C. (2006) Hepatocyte growth factor mediates angiopoietininduced smooth muscle cell recruitment. Blood, 108, 1260-1266.
20. Ma, H., Calderon, T.M., Fallon, J.T. and Berman, J.W. (2002) Hepatocyte growth factor is a survival factor for endothelial cells and is expressed in human atherosclerotic plaques. Atherosclerosis, 164, 79-87.
21. Goodman, T.F. and Abele, D.C. (1971) Multiple glomus tumors. A clinical and electron microscopic study. Arch. Dermatol., 103, 11-23.
22. Brouillard, P., Enjolras, O., Boon, L.M. and Vikkula, M. GLMN and glomuvenous malformation. In Epstein, C., Erickson, R.P. and Wynshaw-Boris, A. (eds), Inborn Errors of Development 2ed, Oxford University Press Inc., in press.
23. Brouillard, P., Ghassibe, M., Penington, A., Boon, L.M., Dompmartin, A., Temple, I.K., Cordisco, M., Adams, D., Piette, F., Harper, J.I. et al. (2005) Four common glomulin mutations cause two thirds of glomuvenous malformations ('familial glomangiomas'): evidence for a founder effect. J. Med. Genet., 42, e13.
24. O'Hagan, A.H., Maloney, F., Buckley, C., Bingham, E.A., Walsh, M.Y., McKenna, K.E., McGibbon, D. and Hughes, A.E. (2006) Mutation analysis in Irish families with glomuvenous malformations. Br. J. Dermatol., 154, 450-452.
25. McIntyre, B.A., Brouillard, P., Aerts, V., Gutierrez-Roelens, I. and Vikkula, M. (2004) Glomulin is predominantly expressed in vascular smooth muscle cells in the embryonic and adult mouse. Gene Expr Patterns, 4, 351-358.
26. Chen, Y.G., Liu, F. and Massague, J. (1997) Mechanism of TGFbeta receptor inhibition by FKBP12. EMBO J., 16, 3866-3876.
27. Grisendi, S., Chambraud, B., Gout, I., Comoglio, P.M. and Crepaldi, T. (2001) Ligand-regulated binding of FAP68 to the hepatocyte growth factor receptor. J. Biol. Chem., 276, 46632-46638.
28. Arai, T., Kasper, J.S., Skaar, J.R., Ali, S.H., Takahashi, C. and DeCaprio, J.A. (2003) Targeted disruption of p185/Cul7 gene results in abnormal vascular morphogenesis. Proc. Natl Acad. Sci. USA, 100, 9855-9860.
29. Antonelli-Orlidge, A., Saunders, K.B., Smith, S.R. and D'Amore, P.A. (1989) An activated form of transforming growth factor beta is produced by cocultures of endothelial cells and pericytes. Proc. Natl Acad. Sci. USA, 86, 4544-4548.
30. Jacobs, A.H. and Walton, R.G. (1976) The incidence of birthmarks in the neonate. Pediatrics, 58, 218-222.
31. Mulliken, J.B. and Young, A.E. (1988) Vascular Birthmarks: Hemangiomas and Malformations. WB Saunders, Philadelphia.
32. Smoller, B.R. and Rosen, S. (1986) Port-wine stains. A disease of altered neural modulation of blood vessels? Arch. Dermatol., 122, 177-179.
33. Breugem, C.C., Alders, M., Salieb-Beugelaar, G.B., Mannens, M.M., Van der Horst, C.M. and Hennekam, R.C. (2002) A locus for hereditary capillary malformations mapped on chromosome 5q. Hum. Genet., 110, 343-347.
34. Eerola, I., Boon, L.M., Watanabe, S., Grynberg, H., Mulliken, J.B. and Vikkula, M. (2002) Locus for susceptibility for familial capillary malformation ('port-wine stain') maps to 5q. Eur. J. Hum. Genet., 10, 375-380.
35. Eerola, I., Boon, L.M., Mulliken, J.B., Burrows, P.E., Dompmartin, A., Watanabe, S., Vanwijck, R. and Vikkula, M. (2003) Capillary malformation-arteriovenous malformation, a new clinical and genetic disorder caused by RASA1 mutations. Am. J. Hum. Genet., 73, 1240-1249.
36. Grewal, T., Evans, R., Rentero, C., Tebar, F., Cubells, L., de Diego, I., Kirchhoff, M.F., Hughes, W.E., Heeren, J., Rye, K.A. et al. (2005) Annexin A6 stimulates the membrane recruitment of p120GAP to modulate Ras and Raf-1 activity. Oncogene, 24, 5809-5820.
37. Kulkarni, S.V., Gish, G., van der Geer, P., Henkemeyer, M. and Pawson, T. (2000) Role of p120 Ras-GAP in directed cell movement. J. Cell Biol., 149, 457-470.
38. Yue, Y., Lypowy, J., Hedhli, N. and Abdellatif, M. (2004) Ras GTPase-activating protein binds to Akt and is required for its activation. J. Biol. Chem., 279, 12883-12889.
39. Revencu, N., Boon, L.M., Mulliken, J.B. and Vikkula, M. RASA1 capillary malformation-arteriovenous malformation. In Epstein, C., Erickson, R.P. and Wynshaw-Boris, A. (eds), Inborn Errors of Development 2ed, Oxford University Press, Inc, in press.
40. Henkemeyer, M., Rossi, D.J., Holmyard, D.P., Puri, M.C., Mbamalu, G., Harpal, K., Shih, T.S., Jacks, T. and Pawson, T. (1995) Vascular system defects and neuronal apoptosis in mice lacking ras GTPase-activating protein. Nature, 377, 695-701.
41. Abdalla, S.A. and Letarte, M. (2006) Hereditary haemorrhagic telangiectasia: current views on genetics and mechanisms of disease. J. Med. Genet., 43, 97-110.
42. Guttmacher, A.E., Marchuk, D.A. and White, R.I., Jr (1995) Hereditary hemorrhagic telangiectasia. N. Engl. J. Med., 333, 918-924.
43. Lachlan, K.L., Lucassen, A.M., Bunyan, D.J. and Temple, I.K. (2007) Cowden syndrome and Bannayan-Riley-Ruvalcaba syndrome represent one condition with variable expression and age-related penetrance: a clinical study of 42 individuals with PTEN mutations. J. Med. Genet.
44. Tan, W.H., Baris, H.N., Burrows, P.E., Robson, C.D., Alomari, A.I., Mulliken, J.B., Fishman, S.J. and Irons, M.B. (2007) The spectrum of vascular anomalies in patients with PTEN mutations: implications for diagnosis and management. J. Med. Genet.
45. Krings, T., Ozanne, A., Chng, S.M., Alvarez, H., Rodesch, G. and Lasjaunias, P.L. (2005) Neurovascular phenotypes in hereditary haemorrhagic telangiectasia patients according to age. Review of 50 consecutive patients aged 1 day-60 years. Neuroradiology, 47, 711-720.
46. Savitsky, K., Bar-Shira, A., Gilad, S., Rotman, G., Ziv, Y., Vanagaite, L., Tagle, D.A., Smith, S., Uziel, T., Sfez, S. et al. (1995) A single ataxia telangiectasia gene with a product similar to PI-3 kinase. Science, 268, 1749-1753.
47. Blinkenberg, E.O., Brendehaug, A., Sandvik, A.K., Vatne, O., Hennekam, R.C. and Houge, G. (2007) Angioma serpiginosum with oesophageal papillomatosis is an X-linked dominant condition that maps to Xp11.3-Xq12. Eur. J. Hum. Genet., 15, 543-547.
48. Vikkula, M. (2007) Vascular pathologies: angiogenomics: towards a genetic nosology and understanding of vascular anomalies. Eur. J. Hum. Genet., 15, 821-822.
49. McAllister, K.A., Grogg, K.M., Johnson, D.W., Gallione, C.J., Baldwin, M.A., Jackson, C.E., Helmbold, E.A., Markel, D.S., McKinnon, W.C., Murrell, J. et al. (1994) Endoglin, a TGF-beta binding protein of endothelial cells, is the gene for hereditary haemorrhagic telangiectasia type 1. Nat. Genet., 8, 345-351.
50. Johnson, D.W., Berg, J.N., Baldwin, M.A., Gallione, C.J., Marondel, I., Yoon, S.J., Stenzel, T.T., Speer, M., Pericak-Vance, M.A., Diamond, A. et al. (1996) Mutations in the activin receptor-like kinase 1 gene in hereditary haemorrhagic telangiectasia type 2. Nat. Genet., 13, 189-195.
51. Cole, S.G., Begbie, M.E., Wallace, G.M. and Shovlin, C.L. (2005) A new locus for hereditary haemorrhagic telangiectasia (HHT3) maps to chromosome 5. J. Med. Genet., 42, 577-582.
52. Bayrak-Toydemir, P., McDonald, J., Akarsu, N., Toydemir, R.M., Calderon, F., Tuncali, T., Tang, W., Miller, F. and Mao, R. (2006) A fourth locus for hereditary hemorrhagic telangiectasia maps to chromosome 7. Am J Med Genet A, 140, 2155-2162.
53. Gallione, C.J., Repetto, G.M., Legius, E., Rustgi, A.K., Schelley, S.L., Tejpar, S., Mitchell, G., Drouin, E., Westermann, C.J. and Marchuk, D.A. (2004) A combined syndrome of juvenile polyposis and hereditary haemorrhagic telangiectasia associated with mutations in MADH4 (SMAD4). Lancet, 363, 852-859.
54. Goumans, M.J., Valdimarsdottir, G., Itoh, S., Rosendahl, A., Sideras, P. and ten Dijke, P. (2002) Balancing the activation state of the endothelium via two distinct TGF-beta type I receptors. EMBO J., 21, 1743-1753.
55. Lebrin, F., Goumans, M.J., Jonker, L., Carvalho, R.L., Valdimarsdottir, G., Thorikay, M., Mummery, C., Arthur, H.M. and ten Dijke, P. (2004) Endoglin promotes endothelial cell proliferation and TGF-beta/ALK1 signal transduction. EMBO J., 23, 4018-4028.
56. Oh, S.P., Seki, T., Goss, K.A., Imamura, T., Yi, Y., Donahoe, P.K., Li, L., Miyazono, K., ten Dijke, P., Kim, S. et al. (2000) Activin receptor-like kinase 1 modulates transforming growth factor-beta 1 signaling in the regulation of angiogenesis. Proc. Natl Acad. Sci. USA, 97, 2626-2631.
57. Urness, L.D., Sorensen, L.K. and Li, D.Y. (2000) Arteriovenous malformations in mice lacking activin receptor-like kinase-1. Nat. Genet., 26, 328-331.
58. Arthur, H.M., Ure, J., Smith, A.J., Renforth, G., Wilson, D.I., Torsney, E., Charlton, R., Parums, D.V., Jowett, T., Marchuk, D.A. et al. (2000) Endoglin, an ancillary TGFbeta receptor, is required for extraembryonic angiogenesis and plays a key role in heart development. Dev. Biol., 217, 42-53.
59. Bourdeau, A., Dumont, D.J. and Letarte, M. (1999) A murine model of hereditary hemorrhagic telangiectasia. J. Clin. Invest., 104, 1343-1351.
60. Sorensen, L.K., Brooke, B.S., Li, D.Y. and Urness, L.D. (2003) Loss of distinct arterial and venous boundaries in mice lacking endoglin, a vascular-specific TGFbeta coreceptor. Dev. Biol., 261, 235-250.
61. Srinivasan, S., Hanes, M.A., Dickens, T., Porteous, M.E., Oh, S.P., Hale, L.P. and Marchuk, D.A. (2003) A mouse model for hereditary hemorrhagic telangiectasia (HHT) type 2. Hum. Mol. Genet., 12, 473-482.
62. Bourdeau, A., Faughnan, M.E. and Letarte, M. (2000) Endoglin-deficient mice, a unique model to study hereditary hemorrhagic telangiectasia. Trends Cardiovasc. Med., 10, 279-285.
63. Scharpfenecker, M., van Dinther, M., Liu, Z., van Bezooijen, R.L., Zhao, Q., Pukac, L., Lowik, C.W. and ten Dijke, P. (2007) BMP-9 signals via ALK1 and inhibits bFGF-induced endothelial cell proliferation and VEGF-stimulated angiogenesis. J. Cell Sci., 120, 964-972.
64. David, L., Mallet, C., Mazerbourg, S., Feige, J.J. and Bailly, S. (2007) Identification of BMP9 and BMP10 as functional activators of the orphan activin receptor-like kinase 1 (ALK1) in endothelial cells. Blood, 109, 1953-1961.
65. Sirard, C., de la Pompa, J.L., Elia, A., Itie, A., Mirtsos, C., Cheung, A., Hahn, S., Wakeham, A., Schwartz, L., Kern, S.E. et al. (1998) The tumor suppressor gene Smad4/Dpc4 is required for gastrulation and later for anterior development of the mouse embryo. Genes Dev., 12, 107-119.
66. Del Curling, O., Jr, Kelly, D.L., Jr, Elster, A.D. and Craven, T.E. (1991) An analysis of the natural history of cavernous angiomas. J. Neurosurg., 75, 702-708.
67. Rigamonti, D., Hadley, M.N., Drayer, B.P., Johnson, P.C., Hoenig-Rigamonti, K., Knight, J.T. and Spetzler, R.F. (1988) Cerebral cavernous malformations. Incidence and familial occurrence. N. Engl. J. Med., 319, 343-347.
68. Clatterbuck, R.E., Eberhart, C.G., Crain, B.J. and Rigamonti, D. (2001) Ultrastructural and immunocytochemical evidence that an incompetent blood-brain barrier is related to the pathophysiology of cavernous malformations. J. Neurol. Neurosurg. Psychiatry, 71, 188-192.
69. Laberge-le Couteulx, S., Jung, H.H., Labauge, P., Houtteville, J.P., Lescoat, C., Cecillon, M., Marechal, E., Joutel, A., Bach, J.F. and Tournier-Lasserve, E. (1999) Truncating mutations in CCM1, encoding KRIT1, cause hereditary cavernous angiomas. Nat. Genet., 23, 189-193.
70. Sahoo, T., Johnson, E.W., Thomas, J.W., Kuehl, P.M., Jones, T.L., Dokken, C.G., Touchman, J.W., Gallione, C.J., Lee-Lin, S.Q., Kosofsky, B. et al. (1999) Mutations in the gene encoding KRIT1, a Krev-1/rap1a binding protein, cause cerebral cavernous malformations (CCM1). Hum. Mol. Genet., 8, 2325-2333.
71. Denier, C., Goutagny, S., Labauge, P., Krivosic, V., Arnoult, M., Cousin, A., Benabid, A.L., Comoy, J., Frerebeau, P., Gilbert, B. et al. (2004) Mutations within the MGC4607 gene cause cerebral cavernous malformations. Am. J. Hum. Genet., 74, 326-337.
72. Liquori, C.L., Berg, M.J., Siegel, A.M., Huang, E., Zawistowski, J.S., Stoffer, T., Verlaan, D., Balogun, F., Hughes, L., Leedom, T.P. et al. (2003) Mutations in a gene encoding a novel protein containing a phosphotyrosine-binding domain cause type 2 cerebral cavernous malformations. Am. J. Hum. Genet., 73, 1459-1464.
73. Bergametti, F., Denier, C., Labauge, P., Arnoult, M., Boetto, S., Clanet, M., Coubes, P., Echenne, B., Ibrahim, R., Irthum, B. et al. (2005) Mutations within the programmed cell death 10 gene cause cerebral cavernous malformations. Am. J. Hum. Genet., 76, 42-51.
74. Liquori, C.L., Berg, M.J., Squitieri, F., Ottenbacher, M., Sorlie, M., Leedom, T.P., Cannella, M., Maglione, V., Ptacek, L., Johnson, E.W. et al. (2006) Low frequency of PDCD10 mutations in a panel of CCM3 probands: potential for a fourth CCM locus. Hum. Mutat., 27, 118.
75. Revencu, N. and Vikkula, M. (2006) Cerebral cavernous malformation: new molecular and clinical insights. J. Med. Genet., 43, 716-721.
76. Kehrer-Sawatzki, H., Wilda, M., Braun, V.M., Richter, H.P. and Hameister, H. (2002) Mutation and expression analysis of the KRIT1 gene associated with cerebral cavernous malformations (CCM1). Acta Neuropathol. (Berl.), 104, 231-240.
77. Gault, J., Shenkar, R., Recksiek, P. and Awad, I.A. (2005) Biallelic somatic and germ line CCM1 truncating mutations in a cerebral cavernous malformation lesion. Stroke, 36, 872-874.
78. Eerola, I., Plate, K.H., Spiegel, R., Boon, L.M., Mulliken, J.B. and Vikkula, M. (2000) KRIT1 is mutated in hyperkeratotic cutaneous capillary-venous malformation associated with cerebral capillary malformation. Hum. Mol. Genet., 9, 1351-1355.
79. Denier, C., Gasc, J.M., Chapon, F., Domenga, V., Lescoat, C., Joutel, A. and Tournier-Lasserve, E. (2002) Krit1/cerebral cavernous malformation 1 mRNA is preferentially expressed in neurons and epithelial cells in embryo and adult. Mech. Dev., 117, 363-367.
80. Guzeloglu-Kayisli, O., Kayisli, U.A., Amankulor, N.M., Voorhees, J.R., Gokce, O., DiLuna, M.L., Laurans, M.S., Luleci, G. and Gunel, M. (2004) Krev1 interaction trapped-1/cerebral cavernous malformation-1 protein expression during early angiogenesis. J. Neurosurg., 100, 481-487.
81. Seker, A., Pricola, K.L., Guclu, B., Ozturk, A.K., Louvi, A. and Gunel, M. (2006) CCM2 expression parallels that of CCM1. Stroke, 37, 518-523.
82. Zawistowski, J.S., Serebriiskii, I.G., Lee, M.F., Golemis, E.A. and Marchuk, D.A. (2002) KRIT1 association with the integrin-binding protein ICAP-1: a new direction in the elucidation of cerebral cavernous malformations (CCM1) pathogenesis. Hum. Mol. Genet., 11, 389-396.
83. Zhang, J., Clatterbuck, R.E., Rigamonti, D., Chang, D.D. and Dietz, H.C. (2001) Interaction between krit1 and icap1alpha infers perturbation of integrin beta1-mediated angiogenesis in the pathogenesis of cerebral cavernous malformation. Hum. Mol. Genet., 10, 2953-2960.
84. Chang, D.D., Wong, C., Smith, H. and Liu, J. (1997) ICAP-1, a novel beta1 integrin cytoplasmic domain-associated protein, binds to a conserved and functionally important NPXY sequence motif of beta1 integrin. J. Cell Biol., 138, 1149-1157.
85. Zhang, X.A. and Hemler, M.E. (1999) Interaction of the integrin beta1 cytoplasmic domain with ICAP-1 protein. J. Biol. Chem., 274, 11-19.
86. Gunel, M., Laurans, M.S., Shin, D., DiLuna, M.L., Voorhees, J., Choate, K., Nelson-Williams, C. and Lifton, R.P. (2002) KRIT1, a gene mutated in cerebral cavernous malformation, encodes a microtubule-associated protein. Proc. Natl Acad. Sci. USA, 99, 10677-10682.
87. Plummer, N.W., Gallione, C.J., Srinivasan, S., Zawistowski, J.S., Louis, D.N. and Marchuk, D.A. (2004) Loss of p53 sensitizes mice with a mutation in Ccm1 (KRIT1) to development of cerebral vascular malformations. Am. J. Pathol., 165, 1509-1518.
88. Petit, N., Blecon, A., Denier, C. and Tournier-Lasserve, E. (2006) Patterns of expression of the three cerebral cavernous malformation (CCM) genes during embryonic and postnatal brain development. Gene Expr Patterns, 6, 495-503.
89. Plummer, N.W., Squire, T.L., Srinivasan, S., Huang, E., Zawistowski, J.S., Matsunami, H., Hale, L.P. and Marchuk, D.A. (2006) Neuronal expression of the Ccm2 gene in a new mouse model of cerebral cavernous malformations. Mamm. Genome, 17, 119-128.
90. Zawistowski, J.S., Stalheim, L., Uhlik, M.T., Abell, A.N., Ancrile, B.B., Johnson, G.L. and Marchuk, D.A. (2005) CCM1 and CCM2 protein interactions in cell signaling: implications for cerebral cavernous malformations pathogenesis. Hum. Mol. Genet., 14, 2521-2531.
91. Uhlik, M.T., Abell, A.N., Johnson, N.L., Sun, W., Cuevas, B.D., Lobel-Rice, K.E., Horne, E.A., Dell'Acqua, M.L. and Johnson, G.L. (2003) Rac-MEKK3-MKK3 scaffolding for p38 MAPK activation during hyperosmotic shock. Nat. Cell. Biol., 5, 1104-1110.
92. Whimster, I.W. (1976) The pathology of lymphangioma circumscriptum. Br. J. Dermatol., 94, 473-486.
93. Dale, R.F. (1985) The inheritance of primary lymphoedema. J. Med. Genet., 22, 274-278.
94. Daniel-Spiegel, E., Ghalamkarpour, A., Spiegel, R., Weiner, E., Vikkula, M., Shalev, E. and Shalev, S.A. (2005) Hydrops fetalis: an unusual prenatal presentation of hereditary congenital lymphedema. Prenat. Diagn., 25, 1015-1018.
95. Ghalamkarpour, A., Morlot, S., Raas-Rothschild, A., Utkus, A., Mulliken, J.B., Boon, L.M. and Vikkula, M. (2006) Hereditary lymphedema type I associated with VEGFR3 mutation: the first de novo case and atypical presentations. Clin. Genet., 70, 330-335.
96. Irrthum, A., Karkkainen, M.J., Devriendt, K., Alitalo, K. and Vikkula, M. (2000) Congenital hereditary lymphedema caused by a mutation that inactivates VEGFR3 tyrosine kinase. Am. J. Hum. Genet., 67, 295-301.
97. Karkkainen, M.J., Ferrell, R.E., Lawrence, E.C., Kimak, M.A., Levinson, K.L., McTigue, M.A., Alitalo, K. and Finegold, D.N. (2000) Missense mutations interfere with VEGFR-3 signalling in primary lymphoedema. Nat. Genet., 25, 153-159.
98. Carver, C., Brice, G., Mansour, S., Ostergaard, P., Mortimer, P. and Jeffery, S. (2007) Three children with Milroy disease and de novo mutations in VEGFR3. Clin. Genet., 71, 187-189.
99. Karkkainen, M.J., Saaristo, A., Jussila, L., Karila, K.A., Lawrence, E.C., Pajusola, K., Bueler, H., Eichmann, A., Kauppinen, R., Kettunen, M.I. et al. (2001) A model for gene therapy of human hereditary lymphedema. Proc. Natl Acad. Sci. USA, 98, 12677-12682.
100. Dumont, D.J., Jussila, L., Taipale, J., Lymboussaki, A., Mustonen, T., Pajusola, K., Breitman, M. and Alitalo, K. (1998) Cardiovascular failure in mouse embryos deficient in VEGF receptor-3. Science, 282, 946-949.
101. Bell, R., Brice, G., Child, A.H., Murday, V.A., Mansour, S., Sandy, C.J., Collin, J.R., Brady, A.F., Callen, D.F., Burnand, K. et al. (2001) Analysis of lymphoedema-distichiasis families for FOXC2 mutations reveals small insertions and deletions throughout the gene. Hum. Genet., 108, 546-551.
102. Fang, J., Dagenais, S.L., Erickson, R.P., Arlt, M.F., Glynn, M.W., Gorski, J.L., Seaver, L.H. and Glover, T.W. (2000) Mutations in FOXC2 (MFH-1), a forkhead family transcription factor, are responsible for the hereditary lymphedema-distichiasis syndrome. Am. J. Hum. Genet., 67, 1382-1388.
103. Finegold, D.N., Kimak, M.A., Lawrence, E.C., Levinson, K.L., Cherniske, E.M., Pober, B.R., Dunlap, J.W. and Ferrell, R.E. (2001) Truncating mutations in FOXC2 cause multiple lymphedema syndromes. Hum. Mol. Genet., 10, 1185-1189.
104. Sholto-Douglas-Vernon, C., Bell, R., Brice, G., Mansour, S., Sarfarazi, M., Child, A.H., Smith, A., Mellor, R., Burnand, K., Mortimer, P. et al. (2005) Lymphoedema-distichiasis and FOXC2: unreported mutations, de novo mutation estimate, families without coding mutations. Hum. Genet., 117, 238-242.
105. Petrova, T.V., Karpanen, T., Norrmen, C., Mellor, R., Tamakoshi, T., Finegold, D., Ferrell, R., Kerjaschki, D., Mortimer, P., Yla-Herttuala, S. et al. (2004) Defective valves and abnormal mural cell recruitment underlie lymphatic vascular failure in lymphedema distichiasis. Nat. Med., 10, 974-981.
106. Irrthum, A., Devriendt, K., Chitayat, D., Matthijs, G., Glade, C., Steijlen, P.M., Fryns, J.P., Van Steensel, M.A. and Vikkula, M. (2003) Mutations in the transcription factor gene SOX18 underlie recessive and dominant forms of hypotrichosis-lymphedema-telangiectasia. Am. J. Hum. Genet., 72, 1470-1478.
107. Ghalamkarpour, A., Devriendt, K. and Vikkula, M. SOX18 and the hypotrichosis-lymphedema-telangiectasia syndrome. In Epstein, C., Erickson, R.P. and Wynshaw-Boris, A. (eds), Inborn Errors of Development 2ed, Oxford University Press, Inc, in press.
108. Pennisi, D., Bowles, J., Nagy, A., Muscat, G. and Koopman, P. (2000) Mice null for sox18 are viable and display a mild coat defect. Mol. Cell. Biol., 20, 9331-9336.
109. Pennisi, D., Gardner, J., Chambers, D., Hosking, B., Peters, J., Muscat, G., Abbott, C. and Koopman, P. (2000) Mutations in Sox18 underlie cardiovascular and hair follicle defects in ragged mice. Nat. Genet., 24, 434-437.
110. Hosking, B.M., Wang, S.C., Downes, M., Koopman, P. and Muscat, G.E. (2004) The VCAM-1 gene that encodes the vascular cell adhesion molecule is a target of the Sry-related high mobility group box gene, Sox18. J. Biol. Chem., 279, 5314-5322.
111. Doffinger, R., Smahi, A., Bessia, C., Geissmann, F., Feinberg, J., Durandy, A., Bodemer, C., Kenwrick, S., Dupuis-Girod, S., Blanche, S. et al. (2001) X-linked anhidrotic ectodermal dysplasia with immunodeficiency is caused by impaired NF-kappaB signaling. Nat. Genet., 27, 277-285.
112. Smahi, A., Courtois, G., Vabres, P., Yamaoka, S., Heuertz, S., Munnich, A., Israel, A., Heiss, N.S., Klauck, S.M., Kioschis, P. et al. (2000) Genomic rearrangement in NEMO impairs NF-kappaB activation and is a cause of incontinentia pigmenti. The International Incontinentia Pigmenti (IP) Consortium. Nature, 405, 466-472.
113. Schmidt-Supprian, M., Bloch, W., Courtois, G., Addicks, K., Israel, A., Rajewsky, K. and Pasparakis, M. (2000) NEMO/IKK gamma-deficient mice model incontinentia pigmenti. Mol. Cell, 5, 981-992.
114. Aagenaes, O. (1974) Hereditary recurrent cholestasis with lymphoedema-two new families. Acta Paediatr. Scand., 63, 465-471.
115. Morris, A.A., Sequeira, J.S., Malone, M., Slaney, S.F. and Clayton, P.T. (1997) Parent-child transmission of infantile cholestasis with lymphoedema (Aagenaes syndrome). J. Med. Genet., 34, 852-853.
116. Bull, L.N., Roche, E., Song, E.J., Pedersen, J., Knisely, A.S., van Der Hagen, C.B., Eiklid, K., Aagenaes, O. and Freimer, N.B. (2000) Mapping of the locus for cholestasis-lymphedema syndrome (Aagenaes syndrome) to a 6.6-cM interval on chromosome 15q. Am. J. Hum. Genet., 67, 994-999.